Free tool
FAERS Monitor: Gonal-F Rff Redi-Ject
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 021684 or its brand name (Gonal-F Rff Redi-Ject, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.
Reports
54
Serious
46
85% of reports
Hospitalization
21
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome21
- off label use7
- foetal exposure during pregnancy6
- maternal exposure during pregnancy5
- abdominal distension4
- arnold-chiari malformation4
- drug interaction4
- exposure during pregnancy4
- hyperthyroidism4
- spina bifida4
- dyspnoea3
- optic nerve sheath meningioma3
- palpitations3
- tachycardia3
- abdominal discomfort2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 2 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| optic nerve sheath meningiomaSignal | 3 | 61561.7 | 18764.0 | 110,760 |
| ovarian hyperstimulation syndromeSignal | 21 | 3541.4 | 2528.7 | 70,199 |
| arnold-chiari malformationSignal | 4 | 1641.6 | 638.0 | 5,000 |
| spina bifidaSignal | 4 | 749.4 | 291.6 | 2,284 |
| hyperthyroidismSignal | 4 | 107.7 | 41.9 | 323 |
| foetal exposure during pregnancySignal | 6 | 28.8 | 13.5 | 135 |
| exposure during pregnancySignal | 4 | 25.1 | 9.8 | 70 |
| maternal exposure during pregnancySignal | 5 | 21.9 | 9.5 | 80 |
| abdominal distensionSignal | 4 | 14.9 | 5.8 | 39 |
| tachycardiaSignal | 3 | 13.2 | 4.4 | 23 |
| palpitationsSignal | 3 | 10.0 | 3.3 | 16 |
| drug interactionSignal | 4 | 9.8 | 3.8 | 24 |
| abdominal discomfort | 2 | 4.6 | 1.2 | 3 |
| off label useSignal | 7 | 3.1 | 1.6 | 8 |
| dyspnoea | 3 | 2.1 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.